Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
暂无分享,去创建一个
[1] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[2] A. D. Schryver,et al. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .
[3] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[4] W. T. Sawyer,et al. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Giampietro Gasparini,et al. Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .
[6] Anthony Howell,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .
[7] B. Trock,et al. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. , 1997, Journal of the National Cancer Institute.
[8] Jack Cuzick,et al. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .
[9] Mike Clarke,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .
[10] R. Collins,et al. Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.
[11] B Fisher,et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.
[12] W. McGuire,et al. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.
[13] C. D. HAAGENSEN,et al. Diseases of the Breast , 1972 .
[14] E. J. Gregory,et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.
[15] Thomas J. Smith,et al. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[17] P. Ravdin,et al. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.